Isaac Motamarry, MD
Surgery · Gainesville, FLNPI 1619110186
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $100,000 of the $114,539 with a category attached, or 87.3%. Centinel Spine, LLC accounts for 87.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $102,286 and has fallen 98.5% since, to $1,538 in 2025. Among surgery clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $698.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Centinel Spine, LLC$100K
- Intuitive Surgical$7K
- W. L. Gore & Associates, Inc.$5K
- AbbVie$533
- Davol Inc.$219
- Kerecis Limited$153
- plus $1K from 23 others
Across 7 payments — averaging $21,429 each. An ownership or investment interest held by the physician or an immediate family member.
- Centinel Spine, LLC$100K
- Durastat LLC$50K
What the payments were for
- Speaking & faculty fees$6951%
- Travel & lodging$2,3732%
- Food & beverage$8,4717%
- Education$3,0003%
- Ownership interest$100,00087%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Centinel Spine, LLC | 1 | $100,000 |
| Intuitive Surgical | 29 | $7,418 |
| W. L. Gore & Associates, Inc. | 62 | $5,085 |
| AbbVie(2 entities) | 7 | $533 |
| Davol Inc. | 4 | $219 |
| Kerecis Limited | 3 | $153 |
| Novo Nordisk | 8 | $142 |
| Merck | 6 | $136 |
| Redhill Biopharma Inc. | 6 | $105 |
| Smith+Nephew | 3 | $72 |
| TELA Bio, Inc. | 4 | $71 |
| Activ Surgical, Inc. | 1 | $67 |
| Medtronic | 1 | $60 |
| Endo Pharmaceuticals Inc. | 3 | $53 |
| Coloplast | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Kvk-tech, Inc. | 7 | $43 |
| Integra Lifesciences Corporation | 2 | $41 |
| Conmed Corporation | 1 | $40 |
| Pacira Pharmaceuticals Incorporated | 2 | $39 |
| Innovation Technologies Inc | 1 | $29 |
| Hologic Inc | 2 | $28 |
| Johnson & Johnson | 1 | $21 |
| Heron Therapeutics, Inc. | 1 | $20 |
| Organogenesis Inc. | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| KCI USA, Inc. | 1 | $15 |
| Reprise Biomedical, Inc. | 1 | $13 |
| Acell, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,704
- GORE ENFORM Preperitoneal Biomaterial$1,692
- GORE SEAMGUARD Bioabsorbable Staple Line Reinforce$1,281
- GORE ENFORM Intraperitoneal Biomaterial$471
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS$372
- GORE ENFORM Biomaterial$259
- PHASIX$125
- SEAMGUARD Bioabsorbable Staple Line Reinforcement$110
- GORE SYNECOR Biomaterial$109
How this compares
$114,539 in reported general payments places this provider in the 95th percentile of 1,569 surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 33 | $35,508 |
| EliquisApixaban | 11 | $6,434 |
| CreonLipase/Protease/Amylase | 13 | $4,022 |
| Naltrexone Hcl | 55 | $2,259 |
| Omeprazole | 145 | $1,413 |
| Gabapentin | 41 | $1,087 |
| Bupropion Hcl | 57 | $479 |
| Ondansetron OdtOndansetron | 39 | $463 |
| Sucralfate | 22 | $455 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $422 |
| Topiramate | 79 | $363 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 81 | $360 |
| Methocarbamol | 51 | $275 |
| Lactulose | 12 | $187 |
| Tramadol Hcl | 39 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $142 | $35,50833 claims |
| AbbVieCreon | $533 | $4,02213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,569 surgery providers in Florida.
Other surgery in Gainesville
- Martin RosenthalGainesville$82K
- Jorge FlorinWinter Garden$2.2M
- Amit TaggarTampa$1.4M
- Keith KimCelebration$1.1M
- Richard DiciccoTampa$964K
- Elizabeth DovecLakeland$870K
- Christopher DucoinTampa$808K
- Andre TeixeiraOcala$731K
- Jose ErbellaBradenton$718K
- Anthony GonzalezMiami$686K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.